Sunitinib vs pembrolizumab + axitinib (targeted agent versus immunotherapy + targeted agent)
Overall survival (absolute effect size estimates based on survival rate at 12 months) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Sunitinib probably leads to higher overall survival (absolute effect size estimates based on survival… compared with pembrolizumab + axitinib (targeted agent versus immunotherapy +… (moderate certainty).
1 finding from 1 review
- HR 1.9 [1.36, 2.65]1 study · 861 participantsModerate